The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patient

Not Applicable

• Conditions: Chronic Hepatitis B

• Registration Number: JPRN-UMIN000016275
• Lead Sponsor: Kinki University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-01-20
• Study Completion: 2019-05-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

*Under 20 years-old *Patients with the past of other IFN and nucleotide analog preparation dosage within the past one year *Patients with a history of the past of hypersensitivity for PEG-IFN-alpha2a or other IFN preparation *Patients with a history of the past of hypersensitivity for biological preparation such as vaccine *Patients with a history of the past of hypersensitivity for an ingredient of Entecavir *Pregnant or lactating patients *Other hepatitis patients like HCV/HDV/HIV *Other chronic liver diseases (autoimmune hepatitis, alcoholic hepatitis, and so on) *Failure of other organs and immunodeficiency patients *Patients with a history or in the presence of severe psychotic depression or other severe psychotic diseases patients *Inappropriate for this study patients

Study & Design

• Study Type: Interventional,observational
• Study Design: Not specified